

communication. It is possible that among mammals a difference in cellular communication within the SCN exists. For example, in rats the expression of clock genes in the ventrolateral and dorsomedial regions of the SCN can be split in vivo under 22-hour light-dark conditions (49). It is possible that this same susceptibility to dissociation within the tissue allows for increased sensitivity to temperature changes in this species (21).

We have shown that cellular communication within the SCN and between the ventrolateral and dorsomedial SCN confers resistance to temperature resetting. This observation is consistent with the ability of an animal's behavioral rhythms to "free-run" through environmental temperature cycles (18, 19) and suggests that resistance to temperature entrainment in vivo is conferred by the SCN. When communication between cells within the SCN is blocked, the tissue exhibits temperature sensitivity equal in magnitude to that of peripheral tissue, revealing that temperature-sensitive resetting is a cell-autonomous property. Finally, the sensitivity of peripheral clocks to small temperature changes is abolished in the presence of KNK437 or quercetin, thus revealing a critical role of the heat shock response pathway in resetting of circadian clocks to thermal stimuli and in temperature compensation of circadian period.

References and Notes

1. C. S. Pittendrigh, *Cold Spring Harb. Symp. Quant. Biol.* **25**, 159 (1960).
2. A. Balsalobre *et al.*, *Science* **289**, 2344 (2000).
3. F. Damiola *et al.*, *Genes Dev.* **14**, 2950 (2000).
4. K. A. Stokkan, S. Yamazaki, H. Tei, Y. Sakaki, M. Menaker, *Science* **291**, 490 (2001).
5. S. Yamazaki *et al.*, *Science* **288**, 682 (2000).
6. D. K. Welsh, D. E. Logothetis, M. Meister, S. M. Reppert, *Neuron* **14**, 697 (1995).

7. A. Balsalobre, F. Damiola, U. Schibler, *Cell* **93**, 929 (1998).
8. S. H. Yoo *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **101**, 5339 (2004).
9. E. Nagoshi *et al.*, *Cell* **119**, 693 (2004).
10. D. K. Welsh, S. H. Yoo, A. C. Liu, J. S. Takahashi, S. A. Kay, *Curr. Biol.* **14**, 2289 (2004).
11. M. Stratmann, U. Schibler, *J. Biol. Rhythms* **21**, 494 (2006).
12. S. A. Brown, G. Zumbrunn, F. Fleury-Olela, N. Preitner, U. Schibler, *Curr. Biol.* **12**, 1574 (2002).
13. B. Kornmann, O. Schaad, H. Bujard, J. S. Takahashi, U. Schibler, *PLoS Biol.* **5**, e34 (2007).
14. F. T. Glaser, R. Stanewsky, *Curr. Biol.* **15**, 1352 (2005).
15. K. Lahiri *et al.*, *PLoS Biol.* **3**, e351 (2005).
16. Y. Liu, M. Merrow, J. J. Loros, J. C. Dunlap, *Science* **281**, 825 (1998).
17. T. Yoshida, Y. Murayama, H. Ito, H. Kageyama, T. Kondo, *Proc. Natl. Acad. Sci. U.S.A.* **106**, 1648 (2009).
18. L. Rensing, P. Ruoff, *Chronobiol. Int.* **19**, 807 (2002).
19. K. Hoffmann, *Oecologia* **3**, 184 (1969).
20. L. M. Prolo, J. S. Takahashi, E. D. Herzog, *J. Neurosci.* **25**, 404 (2005).
21. E. D. Herzog, R. M. Huckfeldt, *J. Neurophysiol.* **90**, 763 (2003).
22. Materials and methods are available as supporting material on Science Online.
23. S. Yamaguchi *et al.*, *Science* **302**, 1408 (2003).
24. C. M. Pennartz, M. T. de Jeu, N. P. Bos, J. Schaap, A. M. Geurtsen, *Nature* **416**, 286 (2002).
25. E. E. Abrahamson, R. Y. Moore, *Brain Res.* **916**, 172 (2001).
26. C. S. Kabrita, F. C. Davis, *Brain Res.* **1195**, 20 (2008).
27. P. L. Lowrey, J. S. Takahashi, *Annu. Rev. Genomics Hum. Genet.* **5**, 407 (2004).
28. H. Reinke *et al.*, *Genes Dev.* **22**, 331 (2008).
29. S. Yokota, M. Kitahara, K. Nagata, *Cancer Res.* **60**, 2942 (2000).
30. S. Honma, K. Honma, T. Shirakawa, T. Hiroshige, *Physiol. Behav.* **44**, 247 (1988).
31. S. Honma, T. Yasuda, A. Yasui, G. T. van der Horst, K. Honma, *J. Biol. Rhythms* **23**, 91 (2008).
32. O. Tataroglu, A. J. Davidson, L. J. Benvenuto, M. Menaker, *J. Biol. Rhythms* **21**, 185 (2006).
33. I. Grad, D. Picard, *Mol. Cell. Endocrinol.* **275**, 2 (2007).
34. S. A. Wadekar, D. Li, E. R. Sánchez, *Mol. Endocrinol.* **18**, 500 (2004).
35. J. Rutter, M. Reick, S. L. McKnight, *Annu. Rev. Biochem.* **71**, 307 (2002).
36. S. G. Ahn, D. J. Thiele, *Genes Dev.* **17**, 516 (2003).
37. A. Balsalobre, L. Marcacci, U. Schibler, *Curr. Biol.* **10**, 1291 (2000).
38. J. S. O'Neill, E. S. Maywood, J. E. Chesham, J. S. Takahashi, M. H. Hastings, *Science* **320**, 949 (2008).
39. H. S. Choi, B. Li, Z. Lin, E. Huang, A. Y. Liu, *J. Biol. Chem.* **266**, 11858 (1991).
40. D. D. Mosser, P. T. Kotzbauer, K. D. Sarge, R. I. Morimoto, *Proc. Natl. Acad. Sci. U.S.A.* **87**, 3748 (1990).
41. S. K. Crosthwaite, J. J. Loros, J. C. Dunlap, *Cell* **81**, 1003 (1995).
42. A. C. Dierfellner, T. Schafmeier, M. W. Merrow, M. Brunner, *Genes Dev.* **19**, 1968 (2005).
43. Y. Liu, N. Y. Garceau, J. J. Loros, J. C. Dunlap, *Cell* **89**, 477 (1997).
44. R. Kaushik *et al.*, *PLoS Biol.* **5**, e146 (2007).
45. R. Stanewsky *et al.*, *Cell* **95**, 681 (1998).
46. K. H. Low, C. Lim, H. W. Ko, I. Edery, *Neuron* **60**, 1054 (2008).
47. J. Majercak, D. Sidote, P. E. Hardin, I. Edery, *Neuron* **24**, 219 (1999).
48. H. Sehadova *et al.*, *Neuron* **64**, 251 (2009).
49. H. O. de la Iglesia, T. Cambras, W. J. Schwartz, A. Díez-Noguera, *Curr. Biol.* **14**, 796 (2004).
50. We thank members of the Takahashi laboratory for helpful discussions; S. Panda and J. B. Hogenesch for providing the U-2 OS cells; S. A. Kay for providing PG 99-465; and R. I. Morimoto for providing HSP70 antibody. We especially thank V. Kumar and K. Shimomura for suggestions and discussion on the manuscript. This work was supported by NIH P50 MH074924 to J.S.T. and T32 AG 20418 to E.D.B. J.S.T. is an Investigator and S.H.Y. was an Associate in the Howard Hughes Medical Institute. J.S.T. has a paid consulting relationship with, and owns stock in, ReSet Therapeutics, Inc., a biotechnology company that works on circadian rhythms and metabolism.

Supporting Online Material

www.sciencemag.org/cgi/content/full/330/6002/379/DC1
Materials and Methods
SOM Text
Figs. S1 to S8
References
29 January 2010; accepted 26 August 2010
10.1126/science.1195262

Cell Type–Specific Loss of BDNF Signaling Mimics Optogenetic Control of Cocaine Reward

Mary Kay Lobo,¹ Herbert E. Covington III,¹ Dipesh Chaudhury,² Allyson K. Friedman,² HaoSheng Sun,¹ Diane Damez-Werno,¹ David M. Dietz,¹ Samir Zaman,¹ Ja Wook Koo,¹ Pamela J. Kennedy,¹ Ezekiel Mouzon,¹ Murtaza Mogri,³ Rachael L. Neve,⁴ Karl Deisseroth,³ Ming-Hu Han,^{1,2} Eric J. Nestler^{1,2*}

The nucleus accumbens is a key mediator of cocaine reward, but the distinct roles of the two subpopulations of nucleus accumbens projection neurons, those expressing dopamine D1 versus D2 receptors, are poorly understood. We show that deletion of TrkB, the brain-derived neurotrophic factor (BDNF) receptor, selectively from D1+ or D2+ neurons oppositely affects cocaine reward. Because loss of TrkB in D2+ neurons increases their neuronal excitability, we next used optogenetic tools to control selectively the firing rate of D1+ and D2+ nucleus accumbens neurons and studied consequent effects on cocaine reward. Activation of D2+ neurons, mimicking the loss of TrkB, suppresses cocaine reward, with opposite effects induced by activation of D1+ neurons. These results provide insight into the molecular control of D1+ and D2+ neuronal activity as well as the circuit-level contribution of these cell types to cocaine reward.

The nucleus accumbens (NAc) plays a crucial role in mediating the rewarding effects of drugs of abuse (1). However, little is known about the specific function of the two major populations of NAc projection neurons, which

together make up >95% of all NAc neurons, in regulating these behaviors. These neurons, like those in the dorsal striatum, are medium spiny neurons (MSNs) divided into two subtypes based on their distinct projections through cortical-basal ganglia

circuits and their differential gene expression, including enrichment of dopamine D1 versus D2 receptors (2). These two MSN subtypes, in dorsal striatum, exert balanced but antagonistic influences on their downstream outputs and behaviors, most notably motor behaviors (3–5), but their role, in NAc, in regulating reward behaviors still needs to be determined.

Although activation of both D1 and D2 receptors contributes to the rewarding effects of cocaine (6), current biochemical evidence has focused primarily on cocaine-induced molecular and structural changes in D1+ MSNs (7–11). For example, the extracellular signal-regulated kinase (ERK) pathway is induced in D1+ MSNs after cocaine exposure (8), an effect thought to be mediated directly via activation of D1 receptors (12, 13). How-

¹Fishberg Department of Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA. ²Pharmacology and System Therapeutics, Mount Sinai School of Medicine, New York, NY 10029, USA. ³Department of Bioengineering, Stanford University, Stanford, CA 94305, USA. ⁴Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

*To whom correspondence should be addressed. E-mail: eric.nestler@mssm.edu

ever, ERK activation by cocaine may occur through other mechanisms, such as brain-derived neurotrophic factor (BDNF) signaling (13), because BDNF and the activated form of its receptor, TrkB, are both up-regulated in the NAc after cocaine exposure (14–16). Furthermore, manipulations of BDNF and its TrkB receptor in this brain region potently modify rewarding responses to cocaine (15–19). Despite these important insights into BDNF signaling and dopaminergic transmission in the NAc, it remains unclear which MSN subtype is involved in these phenomena.

We first determined whether TrkB mRNA is differentially expressed in either MSN subtype using fluorescence activated cell sorting (FACS) to purify each MSN population from NAc and dorsal striatum of bacterial artificial chromosome (BAC) transgenic mice (20, 21) expressing enhanced green fluorescent protein (eGFP) in D1+ or D2+ MSNs (D1-GFP or D2-GFP mice) (fig. S1) (22). TrkB gene expression was observed in both neuron populations (Fig. 1A), similar to previous studies demonstrating TrkB protein in each MSN subtype (23), but we observed a significant enrichment of TrkB mRNA in D2+ MSNs (Fig. 1A). Further studies are needed to confirm this enrichment in D2+ MSNs of the NAc specifically (8).

To assess the functional role of BDNF-TrkB signaling in D1+ and D2+ MSNs, we used D1-Cre or D2-Cre BAC transgenic mice in which Cre recombinase is expressed under D1 or D2 promoters and their regulatory elements (fig. S2) (21, 24), combined with conditional floxed TrkB mice (flTrkB) (25). We then evaluated behavioral responses to cocaine in these mice when TrkB was selectively deleted from D1+ MSNs (D1-




Fig. 1. Effect of selective deletion of TrkB from D1+ or D2+ MSNs on behavioral effects of cocaine, c-Fos induction, and neuronal excitability. (A) TrkB mRNA is expressed in D1+ and D2+ MSNs FACS-purified from D1-GFP and D2-GFP transgenic mice but is significantly enriched in D2+ MSNs ($n = 4$ per group; Student's t test, $P < 0.05$). (B) D1-Cre-flTrkB ($n = 9$) mice displayed enhanced cocaine conditioned place preference (CPP) relative to littermate controls ($n = 10$), whereas (C) D2-Cre-flTrkB mice ($n = 14$) exhibited decreased cocaine CPP compared with littermate controls ($n = 16$) (cocaine dose: 7.5 mg/kg intraperitoneally; Student's t test, $**P < 0.01$, $*P < 0.05$). (D and E) D1-Cre-flTrkB and D2-Cre-flTrkB mice and littermate controls were treated with saline on day 0 and with cocaine (10 mg/kg) on days 1 to 7, and locomotor activity was assessed over a 30-min time period. (D) D1-Cre-flTrkB mice ($n = 6$) displayed enhanced cocaine-induced locomotor activity after repeated cocaine administration compared with littermate controls ($n = 7$) [repeated measures two-way analysis of variance (ANOVA), genotype effect: $F_{(1,11)} = 6.20$, $P < 0.05$; day effect: $F_{(6,66)} = 5.50$, $P < 0.01$], while (E) D2-Cre-flTrkB mice ($n = 10$) showed decreased locomotor activity to acute and repeated cocaine relative to controls ($n = 14$) (repeated measures two-way ANOVA, genotype effect: $F_{(1,22)} = 9.98$, $P < 0.01$; day effect: $F_{(6,132)} = 4.00$, $P < 0.01$). Post hoc analysis reveals significant differences on specific cocaine days (Student's t test, $**P < 0.01$, $*P < 0.05$). Data represented

as mean \pm SEM. (F to I) c-Fos induction was examined 90 min after acute cocaine (20 mg/kg) by double immunolabeling of c-Fos and Cre in the NAc. (F and H) D1-Cre-flTrkB mice exhibited a significant decrease in double-labeled c-Fos (green) and Cre (red) neurons in the NAc after cocaine exposure compared with D1-Cre control mice, and this down-regulation is specific to the NAc shell. (G and I) In contrast, D2-Cre-flTrkB mice, relative to D2-Cre controls, displayed an increase in double-labeled c-Fos and Cre neurons in the NAc, an effect also specific to the NAc shell ($n = 4$ per group, Student's t test, $**P < 0.01$, $*P < 0.05$). Images displayed are from the NAc shell. Arrows represent neurons double labeled with c-Fos and Cre. Arrowheads represent c-Fos neurons that are not Cre positive. Scale bars, 20 μ m. Data represented as mean \pm SEM. (J) Sample traces obtained by 200 pA current injection (holding potential at -80 mV) in NAc shell MSNs in D1-Cre-flTrkB, D2-Cre-flTrkB, and their control mice injected with DIO-AAV-EYFP into the NAc for visualization of D1+ or D2+ MSNs. (K and L) D2+ MSNs in D2-Cre-flTrkB NAc ($n = 3$ animals), but not from D1+ MSNs in D1-Cre-flTrkB NAc ($n = 4$), display increased cell excitability after incremental steps in current injections (100, 150, and 200 pA) compared with respective controls, D2-Cre ($n = 5$) and D1-Cre ($n = 8$). Two-way ANOVA, $F_{(1,7)} = 13.23$, $P = 0.002$ (for D2+ MSNs), $F_{(1,11)} = 4.04$, $P = 0.054$ (for D1+ MSNs). Post hoc analysis reveals significant effects for 100 and 150 pA currents in D2+ MSNs, Student's t test, $*P < 0.05$.

Cre-*flTrkB*) or D2+ MSNs (D2-Cre-*flTrkB*) in the NAC and dorsal striatum. In an unbiased cocaine conditioned place preference (CPP) paradigm, D1-Cre-*flTrkB* mice displayed a significant increase in cocaine preference relative to littermate controls (Fig. 1B). This increase in preference is opposite to findings from previous studies that disrupted BDNF-TrkB signaling nonselectively (i.e., in both MSN subtypes) in the NAC (15–19). However, our observations in the D2-Cre-*flTrkB* mice parallel these previous studies: D2-Cre-*flTrkB* mice exhibited a significant decrease in cocaine preference compared with their littermate controls (Fig. 1C). Importantly, these

behavioral responses are likely mediated by loss of TrkB in D1+ and D2+ MSNs in the adult NAC, because both phenotypes were rescued by expressing TrkB, using herpes simplex virus (HSV-TrkB-GFP-mCherry), in the NAC of each mutant mouse line (fig. S3). The lack of developmental consequences of the TrkB deletion is also supported by several normal baseline behaviors in these mice (fig. S4).

To further explore the effects of selective deficits in BDNF-TrkB signaling on cocaine action, we analyzed locomotor activity and sensitization in the D1-Cre-*flTrkB* and D2-Cre-*flTrkB* mice. Cocaine and other stimulants increase locomotor

activity upon initial exposures, with further increases (sensitization) seen after repeated exposure to the drug. Locomotor sensitization is thought to reflect biochemical adaptations that contribute to drug addiction and relapse (26). In agreement with our CPP experiments, we observed increased locomotor sensitization in D1-Cre-*flTrkB* mice compared with littermate controls and the opposite effect in D2-Cre-*flTrkB* mice (Fig. 1, D and E, and fig. S5).

To gain insight into the functional effect of the loss of BDNF-TrkB signaling from D1+ and D2+ neurons, we first measured c-Fos induction, a marker of neuronal function, in the NAC of D1-




Fig. 2. In vivo and in vitro optogenetic control of D1+ or D2+ MSNs. (A and B) DIO-AAV-ChR2-EYFP or DIO-AAV-EYFP was injected into the NAC of D1-Cre and D2-Cre mice, resulting in ChR2-EYFP or EYFP expressing neurons (green) that also express Cre (red). Scale bars, 50 μ m (low-power images) and 20 μ m (high-power images). (C) Diagram of D1+ or D2+ ChR2 expressing MSNs and blue-light emission from the optic fiber. (D) Control of neuronal firing when a NAC MSN expressing DIO-AAV-ChR2-EYFP is exposed to blue light at 1.4 or 1.0 Hz. (E) c-Fos (red) expression is induced in

D1+ or D2+ MSNs expressing ChR2 (green) that have been activated with 10-Hz blue-light stimulation but not EYFP expressing MSNs. Scale bars, 20 μ m. (F) Quantification of (E) shows a significant increase in c-Fos expressing ChR2 expressing D1+ and D2+ MSNs compared with EYFP expressing controls after blue-light exposure ($n = 3$ per group, Student's *t* test, $*P < 0.01$). (G) c-Fos mRNA is significantly up-regulated in the NAC after blue-light pulses in DIO-AAV-ChR2-EYFP expressing D1-Cre and D2-Cre mice ($n = 4$ to 5 per group, Student's *t* test, $**P < 0.01$, $*P < 0.05$).




Fig. 3. Optogenetic activation of D1+ or D2+ MSNs oppositely regulates cocaine reward. **(A)** Illustration of the CPP cocaine/blue-light paradigm. Mice were conditioned to a cocaine/blue-light chamber and a saline/no-light chamber for 30 min. Blue-light pulses (10 Hz) were delivered for four 3-min periods during the 30-min conditioning. **(B and C)** Activating D1+ MSNs in D1-Cre DIO-AAV-ChR2-EYFP mice ($n = 9$) during cocaine (5 mg/kg)/blue-light CPP enhances cocaine reward compared with D1-Cre DIO-AAV-EYFP controls ($n = 10$), whereas activating D2+ MSNs in D2-Cre DIO-AAV-ChR2-EYFP mice ($n = 7$) during cocaine (7.5 mg/kg)/blue-light CPP attenuates cocaine reward relative to D2-Cre DIO-AAV-EYFP controls ($n = 4$) (Student's t test, $**P < 0.01$, $*P < 0.05$). **(D and E)** Optical control of D1+ and D2+ MSNs in D1-Cre and D2-Cre mice expressing DIO-AAV-ChR2-EYFP or DIO-AAV-EYFP in a cocaine-naïve state and 24 hours after 6 days of repeated cocaine (15 mg/kg) results in increased locomotor activity only when D1+ MSNs are activated after cocaine exposure (two-way ANOVA, genotype effect: $F_{(1,22)} = 4.37$, $P < 0.05$; Student's t test $*P < 0.05$)




Fig. 4. Global optogenetic activation of NAc neurons increases the rewarding effects of cocaine and attenuates TrkB-BDNF signaling. **(A)** HSV-mCherry or HSV-ChR2-mCherry (red) were injected into the NAc of wild-type mice. Scale bar, 50 μ m. **(B)** Activation of ChR2 with blue-light (10 Hz) stimulation induces c-Fos (green) expression in HSV-ChR2-mCherry neurons (red), but not in HSV-mCherry neurons (red), after 10-Hz blue light. Scale bar, 25 μ m. **(C)** Quantification of c-Fos positive neurons in B and c-Fos mRNA after 10-Hz blue light shows a significant increase in c-Fos in HSV-ChR2-mCherry expressing NAc compared to HSV-mCherry expressing controls ($n = 3$ to 5 per group, Student's t test, $**P < 0.01$, $*P < 0.05$). **(D)** HSV-ChR2-mCherry (red) injection into the NAc of D1-GFP and D2-GFP mice mediates transgene expression in both D1+ and D2+ MSNs (GFP, green) and **(E)** c-Fos (blue) is induced by light in each MSN (green). Scale bar, 10 μ m. **(F)** Quantification of **(D)** and **(E)** shows HSV-ChR2-mCherry and blue light induced c-Fos equally in D1+ and D2+ MSNs. **(G)** Mice expressing HSV-ChR2-mCherry ($n = 9$) in the NAc displayed enhanced preference for the cocaine (5 mg/kg)/blue-light chamber compared with control mice expressing HSV-mCherry ($n = 8$) (Student's t test, $P < 0.05$). **(H and I)** Blue-light stimulation results in a significant decrease in phospho:total ERK levels (pERK42/ERK42 and pERK44/ERK44) in the NAc of D1-Cre DIO-AAV-ChR2-EYFP mice and mice expressing HSV-ChR2-mCherry relative to their controls (DIO-AAV-EYFP or HSV-mCherry) ($n = 5$ to 8 per group, Student's t test, $*P < 0.05$).

Cre-*flTrkB* and D2-Cre-*flTrkB* mice after acute cocaine exposure (Fig. 1, F to I, and fig. S6). Previous studies have shown the selective induction of c-Fos in D1+ MSNs in response to cocaine (8, 12). D1-Cre-*flTrkB* mice exhibited a significant decrease in c-Fos+ D1+ MSNs in the NAc, an effect specific to the NAc shell and not seen in the NAc core, relative to control mice (Fig. 1, F and H, and fig. S6). In striking contrast, D2-Cre-*flTrkB* mice displayed a significant increase in c-Fos+ D2+ MSNs in the NAc, also specific to shell, compared to controls (Fig. 1, G and I, and fig. S6). We observed no difference in c-Fos expression in dorsal striatum, and saline-treated controls displayed minimal c-Fos induction (fig. S6).

The c-Fos data suggest that loss of BDNF-TrkB signaling alters the function of both D1+ and D2+ NAc neurons, although the nature of the functional changes are difficult to infer, because c-Fos induction, which is often used as a marker of neuronal activation, can also indicate changes in signaling cascades without a change in firing or even neuronal inhibition (27, 28). We thus directly investigated the excitability of each MSN subtype in the NAc shell after loss of TrkB. We observed a dramatic increase in neuronal firing in response to current injections in D2+ MSNs in the D2-Cre-*flTrkB* mice (Fig. 1, J and L). Although no significant change in baseline excitability was observed in D1+ MSNs in the D1-Cre-*flTrkB* mice, there was a trend for increased excitability ($P = 0.054$) (Fig. 1, J and K), and we found down-regulation of five K^+ channel subunits in the NAc of D1-Cre-*flTrkB* mice after repeated exposure to cocaine (table S1), consistent with enhanced excitability of these MSNs as well.

Given these direct links between loss of TrkB and enhanced excitability of NAc MSNs, we next studied directly the influence of increased activity of these MSN subtypes on behavioral responses to cocaine using optogenetic technologies (29–31). We expressed channelrhodopsin-2 (ChR2), a 473-nm blue light-activated cation channel (29), in D1+ or D2+ MSNs in the NAc using D1-Cre and D2-Cre mice and conditional adeno-associated viruses (AAVs), DIO-AAV-ChR2-EYFP and the control DIO-AAV-EYFP, that express only in the presence of Cre recombinase (31) (Fig. 2, A and B). The vectors were stereotaxically injected into the NAc of D1-Cre and D2-Cre mice, followed by a cannula implant to which an optic fiber was secured to deliver blue light directly into the virus-infected NAc (Fig. 2, A to C). This approach enables temporally precise control of NAc neuronal firing (Fig. 2D). To further validate the technique *in vivo*, we demonstrated c-Fos induction after 10-Hz blue-light pulses in D1+ and D2+ MSNs expressing DIO-AAV-ChR2-EYFP (Fig. 2, E to G, and fig. S7).

To evaluate the behavioral response to cocaine when D1+ versus D2+ MSNs are activated selectively, we used a CPP paradigm, in which D1-Cre and D2-Cre mice, expressing DIO-AAV-ChR2-EYFP or DIO-AAV-EYFP in the NAc, were conditioned to cocaine plus 10-Hz blue-light pulses in

one chamber, with saline and no light used for the opposite chamber (Fig. 3A). D1-Cre mice expressing DIO-AAV-ChR2-EYFP in the NAc displayed a significant increase in cocaine/blue-light preference compared with the D1-Cre DIO-AAV-EYFP control group (Fig. 3B). In contrast, D2-Cre mice expressing DIO-AAV-ChR2-EYFP exhibited a significant attenuation of cocaine/blue-light preference relative to controls (Fig. 3C). We observed no difference in blue-light preference in D1-Cre or D2-Cre mice expressing DIO-AAV-ChR2-EYFP in the absence of cocaine (fig. S8). These data implicate a role for activation of D1+ MSNs in enhancing the rewarding effects of cocaine, with activation of D2+ MSNs antagonizing cocaine reward. These findings are consistent with previous studies, in which disruption of glutamatergic NMDA receptor signaling or loss of c-Fos in D1+ MSNs reduced cocaine sensitization or CPP (11, 32). Conversely, ablation of D2+ MSNs increases the locomotor and rewarding effects of another stimulant, amphetamine (33).

We next evaluated locomotor activity when the two NAc MSN subtypes are activated under cocaine-naïve and exposed conditions. We detected no change in locomotion in cocaine-naïve mice when either MSN subtype was activated relative to nonstimulated controls (Fig. 3, D and E). However, 24 hours after 6 days of repeated cocaine administration (15 mg/kg), blue-light pulses to the NAc in D1-Cre mice expressing DIO-AAV-ChR2-EYFP increased locomotor activity compared with controls (Fig. 3D), with no change observed upon activation of D2+ MSNs (Fig. 3E). These data are in accordance with the prevailing model of dorsal striatal function (3–5), which implicates activation of D1+ MSNs in promoting motor function and suggests that repeated exposure to cocaine enhances the output of D1+ MSNs of the NAc.

It is unclear what behavioral effects occur when both MSN subtypes in the NAc are activated during cocaine exposure, which likely occurs through glutamatergic inputs to this brain region. There is evidence implicating a hypoactive NAc in the cocaine-addicted state (34, 35), but data also support activation of some neurons during operant cocaine behaviors and context-dependent cocaine sensitization (34, 36). Additionally, high-frequency deep-brain stimulation of the NAc, which may inhibit neuronal activity, attenuates an animal's reinstatement to cocaine seeking, and excitatory AMPA receptor-mediated glutamatergic transmission has been shown to induce relapse to cocaine addiction (37, 38). We injected herpes simplex viruses, HSV-ChR2-mCherry or HSV-mCherry, into the NAc of wild-type mice (Fig. 4A) to optically control global NAc neuronal activity during cocaine/blue-light CPP (Fig. 3A). We found that HSV-ChR2-mCherry is expressed equally in D1+ and D2+ MSNs (Fig. 4, D and F) and that blue-light exposure induces equivalent c-Fos levels in these neurons (Fig. 4, B, C, E, and F, and fig. S7). Mice expressing HSV-ChR2-mCherry in the NAc displayed enhanced reward to cocaine/blue light relative to control mice (Fig. 4G).

Finally, we probed for changes in the phosphorylated (active) form of ERK (pERK), which is downstream of BDNF-TrkB signaling (13) and is dynamically regulated by both neuronal activation and inhibition (39–41), to further link loss of TrkB with ChR2-induced activation of D1+ and D2+ MSNs. We observed down-regulation of pERK42 and pERK44 in D1-Cre DIO-AAV-ChR2-EYFP-activated NAc compared with controls, with no change seen in D2-Cre DIO-AAV-ChR2-EYFP-activated NAc (Fig. 4, H and I). Similar to selective activation of D1+ MSNs, we observed decreased pERK42 and pERK44 in HSV-ChR2-mCherry activated NAc (Fig. 4, H and I). Thus, optogenetic stimulation of D1+ MSNs impairs a downstream target of BDNF-TrkB signaling, which implicates common downstream effects upon loss of TrkB, and optogenetic activation, in D1+ MSNs, consistent with the common behavioral effects seen under these conditions. Although no change in pERK was observed in stimulated D2+ MSNs, data cited above revealed common induction of c-Fos and increased neuronal excitability upon loss of TrkB and optogenetic stimulation (Fig. 1, G, I, J, and L, and Fig. 2, D to G).

The present study indicates opposite roles for D1+ and D2+ MSNs in mediating the behavioral effects of cocaine. The potent influence of BDNF-TrkB signaling in the NAc on cocaine reward (15–19) is mediated through D2+ MSNs, because TrkB mRNA is enriched in these neurons and selective deletion of TrkB from D2+ MSNs attenuates cocaine reward. Furthermore, deletion of TrkB from D2+ MSNs increases their neuronal excitability and reactivity to cocaine (as evidenced by increased c-Fos induction), and mimics the ability of direct activation of these neurons, via optogenetic tools, to attenuate behavioral responses to cocaine.

Our D1+ MSN data are more complex. We observe enhanced cocaine reward when D1+ MSNs are activated optogenetically and when TrkB is deleted selectively from them; however, the latter results in decreased c-Fos induction by cocaine without a significant change in baseline neuronal excitability. Nonetheless, the down-regulation of several K^+ channel subunits in the NAc of D1-Cre-*flTrkB* mice suggests enhanced neuronal activity in response to cocaine exposure, which is consistent with the behavioral effects seen with optogenetic activation of D1+ MSNs. Our finding of enhanced behavioral responses to cocaine in the D1 TrkB knockouts, when cocaine induction of c-Fos is lost, is partly consistent with the report that deletion of c-Fos in D1+ MSNs potentiates cocaine reward (11), although our data contrast with other observations of this previous study, which may be due to loss of c-Fos in whole striatum in that report. Furthermore, the ability of acute cocaine to induce c-Fos, which occurs selectively in D1+ MSNs, declines with repeated drug administration (8, 12, 42). The blunted c-Fos response, which we see after acute cocaine exposure in D1+ MSNs lacking TrkB, is therefore similar to wild-type D1+ MSNs that have been exposed to repeated cocaine. Finally, we cannot

rule out trans-synaptic effects in these phenomena, for example, the possibility that D2+ MSNs, expressing normal levels of TrkB, may alter cocaine responses of D1+ MSNs in the D1-Cre-*flTrkB* mice, resulting in loss of c-Fos induction.

Together, our data support a model in which loss of TrkB in D2+ MSNs enhances their excitability, which then directly desensitizes the rewarding effects of cocaine. In contrast, loss of TrkB in D1+ MSNs may similarly enhance their activity, but only when exposed to cocaine, as evidenced by K⁺ channel down-regulation, with such activity increasing the rewarding effects of cocaine. These opposite effects exerted by activation of each MSN subtype on cocaine reward is consistent with current models of basal ganglia function, which posit that D1+ versus D2+ MSNs act in opposition through the direct and indirect pathways, respectively, to produce balanced behavioral output (3–5). It is plausible that, in the addicted brain, there may be an imbalance of these two MSNs. This imbalance may occur through an overactive D1+ MSN pathway as well as through decreased activity of D2+ MSNs, the latter mediated via enhanced BDNF-TrkB signaling. Expanding our understanding of the complex control of drug reward by the two main subtypes of NAc MSNs could help steer the development of treatments of drug addiction targeted selectively to D1+ versus D2+ MSN subtypes.

References and Notes

1. S. E. Hyman, R. C. Malenka, E. J. Nestler, *Annu. Rev. Neurosci.* **29**, 565 (2006).

2. C. R. Gerfen, *Annu. Rev. Neurosci.* **15**, 285 (1992).
3. R. L. Albin, A. B. Young, J. B. Penney, *Trends Neurosci.* **12**, 366 (1989).
4. G. E. Alexander, M. R. DeLong, P. L. Strick, *Annu. Rev. Neurosci.* **9**, 357 (1986).
5. A. M. Graybiel, *Curr. Biol.* **10**, R509 (2000).
6. D. W. Self, in *The Dopamine Receptors*, K. A. Neve, Ed. (Humana Press, New York, 2010), pp. 479–524.
7. K. W. Lee et al., *Proc. Natl. Acad. Sci. U.S.A.* **103**, 3399 (2006).
8. J. Bertran-Gonzalez et al., *J. Neurosci.* **28**, 5671 (2008).
9. M. B. Kelz et al., *Nature* **401**, 272 (1999).
10. F. Ambroggi et al., *Nat. Neurosci.* **12**, 247 (2009).
11. J. Zhang et al., *J. Neurosci.* **26**, 13287 (2006).
12. E. Valjent et al., *J. Neurosci.* **20**, 8701 (2000).
13. L. Lu, E. Koya, H. Zhai, B. T. Hope, Y. Shaham, *Trends Neurosci.* **29**, 695 (2006).
14. J. W. Grimm et al., *J. Neurosci.* **23**, 742 (2003).
15. D. L. Graham et al., *Nat. Neurosci.* **10**, 1029 (2007).
16. K. R. Crooks, D. T. Kleven, R. M. Rodriguez, W. C. Wetsel, J. O. McNamara, *Neuropharmacology* **58**, 1067 (2010).
17. D. L. Graham et al., *Biol. Psychiatry* **65**, 696 (2009).
18. A. Bahi, F. Boyer, V. Chandrasekar, J. L. Dreyer, *Psychopharmacology (Berl.)* **199**, 169 (2008).
19. B. A. Horger et al., *J. Neurosci.* **19**, 4110 (1999).
20. S. Gong et al., *Nature* **425**, 917 (2003).
21. E. Valjent, J. Bertran-Gonzalez, D. Hervé, G. Fisone, J. A. Girault, *Trends Neurosci.* **32**, 538 (2009).
22. M. K. Lobo, S. L. Karsten, M. Gray, D. H. Geschwind, X. W. Yang, *Nat. Neurosci.* **9**, 443 (2006).
23. A. Y. Freeman, J. J. Soghomonian, R. C. Pierce, *Neuroscience* **117**, 147 (2003).
24. S. Gong et al., *J. Neurosci.* **27**, 9817 (2007).
25. B. W. Luikart, S. Nef, T. Shipman, L. F. Parada, *Neuroscience* **117**, 847 (2003).
26. T. E. Robinson, K. C. Berridge, *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **363**, 3137 (2008).
27. J. I. Morgan, T. Curran, *Annu. Rev. Neurosci.* **14**, 421 (1991).
28. J. D. Mikkelsen, A. Söderman, A. Kiss, N. Mirza, *Eur. J. Pharmacol.* **519**, 223 (2005).

29. V. Gradinaru et al., *J. Neurosci.* **27**, 14231 (2007).
30. R. D. Aïran, K. R. Thompson, L. E. Fenno, H. Bernstein, K. Deisseroth, *Nature* **458**, 1025 (2009).
31. J. A. Cardin et al., *Nat. Protoc.* **5**, 247 (2010).
32. C. L. Heusner, R. D. Palmiter, *J. Neurosci.* **25**, 6651 (2005).
33. P. F. Durieux et al., *Nat. Neurosci.* **12**, 393 (2009).
34. L. L. Peoples, A. V. Kravitz, K. Guillem, *ScientificWorldJournal* **7**, 22 (2007).
35. W. A. Carlezon Jr., M. J. Thomas, *Neuropharmacology* **56** (suppl. 1), 122 (2009).
36. E. Koya et al., *Nat. Neurosci.* **12**, 1069 (2009).
37. J. L. Cornish, P. W. Kalivas, *J. Neurosci.* **20**, RC89 (2000).
38. F. M. Vassoler et al., *J. Neurosci.* **28**, 8735 (2008).
39. S. Impey, K. Obrietan, D. R. Storm, *Neuron* **23**, 11 (1999).
40. S. Paul, A. C. Nairn, P. Wang, P. J. Lombroso, *Nat. Neurosci.* **6**, 34 (2003).
41. J.-L. Cao et al., *Proc. Natl. Acad. Sci. U.S.A.*, in press (2010).
42. W. Renthal et al., *J. Neurosci.* **28**, 7344 (2008).
43. We thank N. Heintz and P. Greengard (Rockefeller University) and C.R. Gerfen (NIH/NIMH) for providing us with D1-Cre, D2-Cre, D1-GFP, and D2-GFP mice. We thank M. S. Levine and X. W. Yang (UCLA) for providing us with D1-GFP and D2-GFP mice. We thank L. Parada (UTSouthwestern) for providing us with the *flTrkB* mice. We thank V. Lessman (Otto-von-Guericke-Universität) for providing us with the TrkB (full length)-GFP construct. This work was supported by grants from the National Institute on Drug Abuse, and M.K.L. is supported by the Drug Abuse Research Training Program at MSSM (NIDA T32 DA007135-26A2).

Supporting Online Material

www.sciencemag.org/cgi/content/full/330/6002/385/DC1

Materials and Methods

Figs. S1 to S8

Table S1

References

17 February 2010; accepted 8 September 2010

10.1126/science.1188472

Salmonella Pathogenesis and Processing of Secreted Effectors by Caspase-3

C. V. Srikanth,^{1,2*} Daniel M. Wall,^{1,3*} Ana Maldonado-Contreras,² Hai Ning Shi,¹ Daoguo Zhou,⁴ Zachary Demma,² Karen L. Mumy,^{1,2} Beth A. McCormick^{1,2†}

The enteric pathogen *Salmonella enterica* serovar Typhimurium causes food poisoning resulting in gastroenteritis. The *S. Typhimurium* effector *Salmonella* invasion protein A (SipA) promotes gastroenteritis by functional motifs that trigger either mechanisms of inflammation or bacterial entry. During infection of intestinal epithelial cells, SipA was found to be responsible for the early activation of caspase-3, an enzyme that is required for SipA cleavage at a specific recognition motif that divided the protein into its two functional domains and activated SipA in a manner necessary for pathogenicity. Other caspase-3 cleavage sites identified in *S. Typhimurium* appeared to be restricted to secreted effector proteins, which indicates that this may be a general strategy used by this pathogen for processing of its secreted effectors.

Salmonella enterica serovar Typhimurium acquires virulence via a 40-kb segment of the bacterial chromosome designated *Salmonella* pathogenicity island 1 (SPI-1) (1). SPI-1 contains more than 25 genes encoding structural components and substrates of a type III protein-secretion system that mediates the translocation of effector proteins from *Salmonella* into mammalian cells (1). One of these, *Salmonella* invasion protein A (SipA), is a bifunctional molecule responsible for promoting actin polymerization, a process that facilitates bacterial entry into epi-

thelial cells (2), and is required to trigger signal transduction cascades that promote polymorphonuclear leukocyte (PMN) migration across the intestinal epithelium (3). The actin binding function of SipA is known to be localized to a C-terminal fragment (amino acids 426 to 684) termed SipAb (4). We have reported that the N-terminal fragment of the SipA effector protein (amino acids 2 to 425) harbors the functional domain that induces PMN transepithelial migration (5), which underlies the clinical manifestations of salmonellosis.

We found a caspase-3 motif, DEVD (6), at amino acid positions 431 to 434 (Fig. 1A) of SipA at the junction between the two functional domains (7). Treatment of a purified fraction of SipA to activated caspase-3 enzyme generated a predicted fragment (55 kD; Fig. 1B) and confirmed that the SipA DEVD cleavage motif was functionally active. The expected lower molecular weight band was not seen, most likely from lack of antibody recognition; however, mutation of the caspase-3 site by changing aspartic acid at position four to alanine (A) (DEVD→DEVA; termed caspase site mutant, csm-SipA) rendered SipA insensitive to caspase-3 cleavage (Fig. 1B).

Although caspase-3 is a frequently activated death protease, this enzyme also catalyzes specific cleavage of many cellular proteins (8) and promotes cell proliferation and inflammation

¹Department of Pediatric Gastroenterology and Nutrition, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02129, USA. ²Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA. ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK. ⁴Department of Biological Sciences, Purdue University, West Lafayette, IN 47907, USA.

*These authors contributed equally to this work.

†To whom correspondence should be addressed. E-mail: Beth.McCormick@umassmed.edu